Pharmena S.A.
PHR.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| % Growth | -97.3% | 3,190% | -98% | – |
| Cost of Goods Sold | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Gross Profit | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| % Margin | 73.9% | 59.4% | 3,456.5% | 51.5% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| G&A Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| SG&A Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 0 | -PLN 0 | PLN 0 | -PLN 0 |
| Operating Expenses | PLN 0 | -PLN 0 | PLN 0 | PLN 0 |
| Operating Income | -PLN 0 | PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -1,267.5% | 354.5% | -169.9% | -26.2% |
| Other Income/Exp. Net | PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| Pre-Tax Income | -PLN 0 | PLN 0 | -PLN 0 | -PLN 0 |
| Tax Expense | -PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Net Income | -PLN 0 | PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -470.9% | 294.2% | -525.1% | -30.2% |
| EPS | -0.11 | 2.6 | -0.14 | -0.41 |
| % Growth | -104.2% | 1,957.1% | 65.9% | – |
| EPS Diluted | -0.11 | 2.6 | -0.14 | -0.41 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Interest Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Depreciation & Amortization | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| EBITDA | -PLN 0 | PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -1,261.9% | 361.4% | -43.1% | -23.1% |